RGNT Company Profile and Key Details

Regentis Biomaterials Ltd. generated EPS of -$2.67 over the past year. Five-year average earnings growth is -71.58%.

Regentis Biomaterials Ltd. has 7.02 million shares outstanding. The public float is 2.82 million shares, elevated short interest at 1.58% of float. This equals 80.59 thousand shares. The short ratio is 0.01 days. Institutional investors hold 24.44% of the float. Insiders own 14.04%.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Short-term trend indicators are bullishly aligned (SMA20 -15.58%, SMA50 -33.19%, SMA200 -34.87%). The stock’s 14-day RSI is 31.24 (weak momentum), while the ATR of 0.46 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -52.63% below its high and over 6.89% above its low. Average 10-day trading volume of 53.63 thousand shares is below the 3-month average of 5.10 million, indicating normal recent market interest.

Regentis Biomaterials Ltd. (AMEX:RGNT) closed at $2.09 USD, losing -$0.07 (-3.24%) from the previous close of $2.16. The stock is currently mid-range between its 52-week high and low $1.23 and $15.50. With a market capitalization of about $14.68 million, Regentis Biomaterials Ltd. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.69). Key stats such as the average daily volume over the past year has been around 5.41 million shares, volume is running light vs its 52-week average. Headquartered in Herzliya, TA, Regentis Biomaterials Ltd. operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Ehud Geller, the company employs approximately 10 people and listed since December 04, 2025. Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life.

Regentis Biomaterials Ltd. (AMEX:RGNT) shares are flat 5.34% year-to-date currently trading near 52-week highs band.

Our AI price prediction model suggests that Regentis Biomaterials Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected rise of 2799.52%, reaching $60.60 by November 23, 2026, with a range of $60.46 to $60.80. 1-Year Outlook: Projected gain of 173.21%, with price at $5.71 by August 25, 2027, within a range of $5.42 to $5.94.